BCL2L1 and pancreatic neoplasm: A recent study showed synergy between DT2216 (a clinical-stage BCL-XL PROTAC) and sotorasib in KRAS G12C-mutated NSCLC, CRC, and pancreatic cancer preclinical models [76].